Fulcrum Therapeutics (FULC) Share-based Compensation (2018 - 2026)

Fulcrum Therapeutics (FULC) has reported Share-based Compensation for 9 consecutive years, with $22.3 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Share-based Compensation rose 675.65% year-over-year to $22.3 million; the TTM figure through Jun 2026 stood at $22.3 million (up 80.77% YoY), while the FY2025 annual figure was $22.1 million, up 2.31% from the prior year.
• Share-based Compensation fell to $22.3 million in Q2 2026 per FULC's latest filing, from $40.0 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $40.0 million in Q1 2026 and bottomed at $2.5 million in Q4 2024.
• Historically, Share-based Compensation has averaged $7.6 million across 5 years, with a median of $3.6 million in 2023.
• Annual changes were most pronounced in 2025 — Share-based Compensation slumped 33.82% — and 2026, when it jumped 1163.02%.
• Fulcrum Therapeutics' Share-based Compensation stood at $3.3 million in 2022, then rose by 5.44% to $3.4 million in 2023, then decreased by 28.18% to $2.5 million in 2024, then rose by 23.78% to $3.1 million in 2025, then surged by 627.33% to $22.3 million in 2026.
• Business Quant data shows FULC's Share-based Compensation at $22.3 million in Q2 2026, $40.0 million in Q1 2026, and $3.1 million in Q4 2025.